每经AI快讯，凯盛新材（SZ 301069，收盘价：23.39元）10月22日晚间发布三季度业绩公告称，2025年 前三季度营收约7.74亿元，同比增加11.22%；归属于上市公司股东的净利润约1.16亿元，同比增加 121.56%；基本每股收益0.2752元，同比增加121.58%。 （记者 曾健辉） 每经头条（nbdtoutiao）——展望"十五五"|专访贺铿：必须改变以往将资金过度集中于房屋建设和基础 设施建设的倾向，更加突出民生领域投入 截至发稿，凯盛新材市值为98亿元。 ...

截至发稿，凯盛新材市值为98亿元。 每经AI快讯，凯盛新材（SZ 301069，收盘价：23.39元）10月22日晚间发布公告称，公司第四届第三次 董事会会议于2025年10月22日在公司会议室通过"现场+通讯"表决的方式召开。会议审议了《关于增加 2025年度日常关联交易预计额度的议案》等文件。 2025年1至6月份，凯盛新材的营业收入构成为：化工新材料占比99.42%，其他业务占比0.58%。 每经头条（nbdtoutiao）——展望"十五五"|专访贺铿：必须改变以往将资金过度集中于房屋建设和基础 设施建设的倾向，更加突出民生领域投入 （记者 王瀚黎） ...

凯盛新材公告，公司2025年前三季度合并会计报表实现归属于上市公司股东净利润1.16亿元，母公司实 现净利润1.27亿元。公司拟以截至2025年9月30日的总股本4.21亿股为基数，向全体股东每10股派发现金 红利0.50元（含税），送红股0股，不以公积金转增股本。本次利润分配共计派发现金红利总额为 2103.24万元。 ...

凯盛新材公告，2025年第三季度营收为2.42亿元，同比增长19.96%；净利润为2727.06万元，同比增长 1645.49%。前三季度营收为7.74亿元，同比增长11.22%；净利润为1.16亿元，同比增长121.56%。 ...

Financial Performance - The company's revenue for Q3 2025 reached ¥241,545,682.12, representing a year-on-year increase of 19.96%[5] - Net profit attributable to shareholders was ¥27,270,598.11, a significant increase of 1,645.49% compared to the same period last year[5] - The basic earnings per share (EPS) was ¥0.0648, reflecting a year-on-year growth of 1,643.57%[5] - Total operating revenue for the current period reached ¥774,099,034.83, an increase of 11.2% compared to ¥695,989,904.34 in the previous period[21] - Net profit for the current period was ¥115,755,522.87, significantly higher than ¥51,981,530.84 in the previous period, marking a growth of 122.2%[22] - Total comprehensive income attributable to the parent company reached ¥115,755,522.87, compared to ¥52,244,600.58 in the previous period, reflecting a significant increase[23] - Basic and diluted earnings per share both improved to ¥0.2752 from ¥0.1242 year-over-year, indicating strong profitability growth[23] Assets and Liabilities - Total assets at the end of Q3 2025 amounted to ¥2,445,295,360.59, an increase of 2.37% from the end of the previous year[5] - The total assets increased to ¥2,445,295,360.59 from ¥2,388,723,256.19, representing a growth of 2.4%[19] - Total liabilities decreased to ¥713,629,041.53 from ¥752,641,539.99, a reduction of 5.2%[19] - The total current liabilities decreased to ¥174,036,598.83 from ¥237,501,393.93, a decline of 26.8%[19] Equity and Shareholding - The company’s total equity attributable to shareholders increased to ¥1,731,666,319.06, a growth of 5.84% from the previous year[5] - The company's equity attributable to shareholders rose to ¥1,731,666,319.06, compared to ¥1,636,081,716.20, an increase of 5.8%[19] - Total number of common shareholders at the end of the reporting period is 31,375[11] - The largest shareholder, Huabang Life Health, holds 25.49% of shares, totaling 107,216,000 shares[11] - The second-largest shareholder, Huabang Health - Southwest Securities, holds 14.26% of shares, totaling 60,000,000 shares[11] - The total number of restricted shares at the end of the reporting period is 29,440,000, with no shares released during the period[15] Cash Flow and Investments - Cash flow from operating activities for the year-to-date was ¥67,712,718.94, up 46.91% compared to the same period last year[9] - Net cash flow from operating activities was ¥67,712,718.94, up from ¥46,091,360.16 in the previous period, showcasing enhanced operational efficiency[24] - Cash inflow from investment activities totaled ¥3,618,922,070.50, compared to ¥3,439,872,561.02 in the prior period, indicating robust investment returns[24] - The company’s investment activities generated a cash inflow of ¥22,417,733.07, a 106.63% increase compared to the same period last year[9] - Net cash flow from investment activities improved to ¥22,417,733.07 from a negative ¥337,905,321.16, highlighting a turnaround in investment performance[24] - The company reported a decrease in cash outflows from financing activities, totaling ¥43,725,462.59 compared to ¥78,396,198.59 in the previous period, indicating better cash management[24] Income and Expenses - The company reported a significant increase in other income, which reached ¥31,029,702.66, a rise of 4,582.86% year-on-year, primarily due to a technical compensation payment of ¥30 million[9] - The company’s income tax expenses rose by 110.63% to ¥19,276,166.17, driven by an increase in total profit[9] - Total operating costs amounted to ¥679,386,265.33, up from ¥653,215,521.28, reflecting a rise of 4.0%[21] - Research and development expenses were ¥39,639,076.78, slightly up from ¥39,202,196.52, indicating a focus on innovation[22] - The company reported a significant increase in operating profit to ¥104,635,557.55 from ¥61,217,575.59, reflecting a growth of 71.0%[22] Other Information - The company has no preferred shareholders or significant changes in the top ten preferred shareholders[13] - There are no changes in the shareholding structure of the top ten shareholders due to securities lending or borrowing[12] - The company did not execute any mergers or acquisitions during the reporting period, focusing instead on organic growth strategies[25] - The financial report for the third quarter was not audited, which may impact the perceived reliability of the financial data presented[25] - The company plans to adopt new accounting standards starting in 2025, which may affect future financial reporting[25]

西南证券股份有限公司关于山东凯盛新材料股份有限公司 增加 2025 年度日常关联交易预计额度的核查意见 西南证券股份有限公司（以下简称"西南证券"或"保荐机构"）作为山东凯盛 新材料股份有限公司（以下简称"凯盛新材"或"公司"）向不特定对象发行可转换 公司债券的保荐机构，根据《证券发行上市保荐业务管理办法》《深圳证券交易 所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号——创 业板上市公司规范运作》等有关规定，对凯盛新材增加 2025 年度日常关联交易 预计额度的事项进行了核查，具体情况如下： 一、日常关联交易基本情况 （一）日常关联交易概述 凯盛新材分别于 2025 年 3 月 13 日和 2025 年 4 月 11 日召开第三届董事会第 二十九次会议和 2024 年年度股东大会，审议通过了《关于预计 2025 年度日常 关联交易的议案》，具体内容详见公司 2025 年 3 月 15 日于巨潮资讯网 （www.cninfo.com.cn）披露的《关于预计 2025 年度日常关联交易的公告》（公 告编号：2025-008）。 （二）本次增加 2025 年度预计日常关联交易的类别和金额 根据 ...

根据公司日常经营的实际需要，公司本次拟增加 2025 年度与北京颖泰嘉和 生物科技股份有限公司、陕西汉江药业集团股份有限公司的日常性关联交易预计 额度，具体情况如下： 单位：万元 | 证券代码：301069 | 证券简称：凯盛新材 | 公告编号：2025-043 | | --- | --- | --- | | 债券代码：123233 | 债券简称：凯盛转债 | | 山东凯盛新材料股份有限公司 关于增加2025年度日常关联交易预计额度的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，并对公告中的 虚假记载、误导性陈述或者重大遗漏承担责任。 一、日常关联交易基本情况 （一）日常关联交易概述 山东凯盛新材料股份有限公司（以下简称"公司"）分别于 2025 年 3 月 13 日和 2025 年 4 月 11 日召开第三届董事会第二十九次会议和 2024 年年度股东大 会，审议通过了《关于预计 2025 年度日常关联交易的议案》，具体内容详见公司 2025 年 3 月 15 日于巨潮资讯网（www.cninfo.com.cn）披露的《关于预计 2025 年度日常关联交易的公告》（公告编号：2025-008）。 ...

Group 1 - The A-share market saw a significant decline in chemical raw material stocks, with notable drops in several companies [1] - Boyuan Co., Ltd. experienced the largest decline at over 12%, while Chengxing Co., Ltd. fell by over 8% [1] - Other companies such as Haike Xinyuan, Duofluor, and Guanghua Technology also reported declines exceeding 6% [1] Group 2 - Specific stock performance data includes: - Boyuan Co., Ltd. down 12.63% with a market cap of 11.8 billion and a year-to-date increase of 127.50% [2] - Chengxing Co., Ltd. down 8.56% with a market cap of 6.071 billion and a year-to-date increase of 54.66% [2] - Haike Xinyuan down 6.45% with a market cap of 6.105 billion and a year-to-date increase of 109.48% [2] - Duofluor down 6.09% with a market cap of 23.5 billion and a year-to-date increase of 67.08% [2] - Guanghua Technology down 4.04% with a market cap of 9.5 billion and a year-to-date increase of 23.67% [2] - Kaisheng New Materials down 3.29% with a market cap of 9.877 billion and a year-to-date increase of 58.92% [2]

Core Insights - Huabang Health, established in 1992, is a leading enterprise in the field of clinical skin medications and skin health in China [1] - The company has developed a diversified business model focusing on the health industry, with independent operations in agricultural chemicals, new materials, and tourism [1] - Huabang Health's business scope includes five major areas: pharmaceuticals, medical services, agricultural chemicals, new materials, and tourism [1] Business Structure - The company controls three listed subsidiaries: Yingtai Biotechnology (920819.BJ), Kaisheng New Materials (301069.SZ), and Lijiang Co. (002033.SZ) [1] - It also holds a controlling stake in a New Third Board enterprise, Qinling Tourism (870256.NQ), and has a stake in another New Third Board company, Purikin (874090.NQ) [1] Future Strategy - The company plans to adhere to its development strategy in pharmaceuticals and medical health, continuously improving its full industry chain model that integrates raw materials, formulations, functional skincare products, comprehensive skin health management, and medical services [1] - Huabang Health aims to maintain the independent and stable operation of its three listed companies while leveraging its role as a controlling shareholder in governance [1]

本公司及董事会全体成员保证公告内容真实、准确和完整，并对公告中的虚假记载、误导性陈述或者重 大遗漏承担责任。 山东凯盛新材料股份有限公司（以下简称"公司"或"本公司"）近日收到公司控股股东华邦生命健康股份 有限公司（以下简称"华邦健康"）的书面通知，华邦健康面向专业投资者非公开发行可交换公司债券将 进入换股期。具体情况如下： 一、控股股东可交换公司债券的基本情况 华邦健康于2025年4月22日面向专业投资者非公开发行可交换公司债券（以下简称"本期可交换债 券"），并于2025年4月28日起在深圳证券交易所挂牌交易，债券简称"25华邦EB"，债券代码"117227"， 发行规模6亿元，期限3年，初始换股价格为14.88元/股。 2025年4月30日，因公司实施2024年度权益分派，"25华邦EB"的换股价格由14.88元/股调整为14.83元/ 股。 二、控股股东可交换公司债券进入换股期的情况 登录新浪财经APP 搜索【信披】查看更多考评等级 董事会 2025年10月21日 三、其他情况说明及相关风险提示 截至本公告披露日，华邦健康持有本公司股份167,216,000股（其中包括预备用于交换的股票数量为 60, ...